Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2006

01-02-2006 | Letter

The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction

Authors: Alberto Pinzon-Charry, Chris W Schmidt, José Alejandro López

Published in: Breast Cancer Research | Issue 1/2006

Login to get access

Abstract

Overcoming dendritic cell (DC) dysfunction is a prerequisite for successful active immunotherapy against breast cancer. CD40 ligand (CD40L), a key molecule in the interface between T-lymphocytes and DCs, seems to be instrumental in achieving that goal. Commenting on our data that CD40L protects circulating DCs from apoptosis induced by breast tumor products, Lenahan and Avigan highlighted the potential of CD40L for immunotherapy. We expand on that argument by pointing to additional findings that CD40L not only rescues genuine DCs but also functionally improves populations of immature antigen-presenting cells that fill the DC compartment in patients with breast cancer.
Literature
1.
Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol. 2000, 18: 767-811. 10.1146/annurev.immunol.18.1.767.CrossRefPubMed
2.
Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998, 393: 480-483. 10.1038/31002.CrossRefPubMed
3.
Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998, 393: 474-478. 10.1038/30989.CrossRefPubMed
4.
Pinzon-Charry A, Maxwell T, McGuckin MA, Schmidt C, Furnival C, Lopez JA: Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res. 2006, 8: R5-10.1186/bcr1361.CrossRefPubMed
5.
6.
Terheyden P, Straten P, Brocker EB, Kampgen E, Becker JC: CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-γ-producing T cells from tumor-infiltrating lymphocytes. J Immunol. 2000, 164: 6633-6639.CrossRefPubMed
7.
Lopez JA, Hart DN: Current issues in dendritic cell cancer immunotherapy. Curr Opin Mol Ther. 2002, 4: 54-63.PubMed
8.
Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med. 2004, 10: 475-480. 10.1038/nm1039.CrossRefPubMed
9.
Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, et al: Dendritic cells are functionally defective in multiple myeloma: the role of inter-leukin-6. Blood. 2002, 100: 230-237. 10.1182/blood.V100.1.230.CrossRefPubMed
10.
Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997, 3: 483-490.PubMed
11.
Pinzon-Charry A, Ho C, Laherty R, Maxwell T, Walker D, Gardiner R, O'Connor L, Pyke C, Schmidt CW, Furnival C, et al: A population of HLA-DR+ immature cells accumulate in the blood den-dritic cell compartment of patients with different types of cancer. Neoplasia. 2005, 7: 1123-1132. 10.1593/neo.05442.CrossRefPubMedPubMedCentral
12.
Pinzon-Charry A, Maxwell T, Prato S, Furnival C, Schmidt CW, Lopez JA: HLA-DR+ immature cells exhibit reduced antigen presenting cell function but respond to CD40 stimulation. Neoplasia. 2005, 7: 1112-1122. 10.1593/neo.05448.CrossRefPubMedPubMedCentral
Metadata
Title
The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction
Authors
Alberto Pinzon-Charry
Chris W Schmidt
José Alejandro López
Publication date
01-02-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1386

Other articles of this Issue 1/2006

Breast Cancer Research 1/2006 Go to the issue

Research article

Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect

Review

Key stages in mammary gland development: The cues that regulate ductal branching morphogenesis

Research article

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

Commentary

Recent translational research: Oncogene discovery by insertional mutagenesis gets a new boost

Review

Overdiagnosis and overtreatment of breast cancer: Microsimulation modelling estimates based on observed screen and clinical data

Research article

Comprehensive copy number profiles of breast cancer cell model genomes

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits